Join
Live feed
·
PRReleasevia Quantisnow
Atrium Therapeutics Inc. logo

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

ByQuantisnow·Wall Street's wire, on your screen.
RNA· Atrium Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNA (Atrium Therapeutics Inc.) and more on Quantisnow.